• Admin Login
    View Item 
    •   Home
    • Faculty of Education, Health and Wellbeing
    • Faculty of Education, Health and Wellbeing
    • View Item
    •   Home
    • Faculty of Education, Health and Wellbeing
    • Faculty of Education, Health and Wellbeing
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of WIRECommunitiesTitleAuthorsIssue DateSubmit DateSubjectsTypesJournalDepartmentPublisherThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsTypesJournalDepartmentPublisher

    Administrators

    Admin Login

    Local Links

    AboutThe University LibraryOpen Access Publications PolicyDeposit LicenceCOREWIRE Copyright and Reuse Information

    Statistics

    Display statistics

    Quality of Life in men with prostate cancer randomly allocated to receive Docetaxel or Abiraterone in the STAMPEDE Trial

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Rush_et_al_Quality_of_life_in_ ...
    Size:
    826.7Kb
    Format:
    PDF
    Download
    Authors
    Rush, Hannah L
    Murphy, Laura
    Morgans, Alicia K
    Clarke, Noel W
    Cook, Adrian D
    Attard, Gerhardt
    Macnair, Archie
    Dearnaley, David P
    Parker, Christopher C
    Russell, J Martin
    Gillessen, Silke
    Matheson, David
    Millman, Robin
    Brawley, Christopher D
    Pugh, Cheryl
    Tanguay, Jacob S
    Jones, Robert J
    Wagstaff, John
    Rudman, Sarah
    O'Sullivan, Joe M
    Gale, Joanna
    Birtle, Alison
    Protheroe, Andrew
    Gray, Emma
    Perna, Carla
    Tolan, Shaun
    McPhail, Neil
    Malik, Zaf I
    Vengalil, Salil
    Fackrell, David
    Hoskin, Peter
    Sydes, Matthew R
    Chowdhury, Simon
    Gilbert, Duncan C
    Parmar, Mahesh KB
    James, Nicholas D
    Langley, Ruth E
    Show allShow less
    Issue Date
    2021-11-10
    
    Metadata
    Show full item record
    Abstract
    PURPOSE Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data may guide treatment choices. METHODS A group of patients within the STAMPEDE trial were contemporaneously enrolled with the possibility of being randomly allocated to receive either docetaxel + SOC or AAP + SOC. A mixed-model assessed QOL in those who had completed at least one QLQ-C30 + PR25 questionnaire. The primary outcome measure was difference in global-QOL (QLQ-C30 Q29&30) between patients allocated to docetaxel + SOC or AAP + SOC over the 2 years after random assignment, with a predefined criterion for clinically meaningful difference of > 4.0 points. Secondary outcome measures included longitudinal comparison of functional domains, pain, and fatigue, plus global-QOL at defined timepoints. RESULTS Five hundred fifteen patients (173 docetaxel + SOC and 342 AAP + SOC) were included. Baseline characteristics, proportion of missing data, and mean baseline global-QOL scores (docetaxel + SOC 77.8 and AAP + SOC 78.0) were similar. Over the 2 years following random assignment, the mean modeled global-QOL score was +3.9 points (95% CI, +0.5 to +7.2; P = .022) higher in patients allocated to AAP + SOC. Global-QOL was higher for patients allocated to AAP + SOC over the first year (+5.7 points, 95% CI, +3.0 to +8.5; P < .001), particularly at 12 (+7.0 points, 95% CI, +3.0 to +11.0; P = .001) and 24 weeks (+8.3 points, 95% CI, +4.0 to +12.6; P < .001). CONCLUSION Patient-reported QOL was superior for patients allocated to receive AAP + SOC, compared with docetaxel + SOC over a 2-year period, narrowly missing the predefined value for clinical significance. Patients receiving AAP + SOC reported clinically meaningful higher global-QOL scores throughout the first year following random assignment.
    Citation
    Rush, H., Murphy, L., Morgans, A. K., Clarke, N. W. et al (2021) Quality of Life in men with prostate cancer randomly allocated to receive Docetaxel or Abiraterone in the STAMPEDE Trial, Journal of Clinical Oncology, 40(8), pp. 825-836.
    Publisher
    American Society of Clinical Oncology (ASCO)
    Journal
    Journal of Clinical Oncology
    URI
    http://hdl.handle.net/2436/624443
    DOI
    10.1200/jco.21.00728
    Additional Links
    https://ascopubs.org/doi/abs/10.1200/JCO.21.00728
    Type
    Journal article
    Language
    en
    Description
    This is a copy of an article published by American Society of Clinical Oncology in Journal of Clinical Oncology on 10/11/2021, available online: https://ascopubs.org/doi/abs/10.1200/JCO.21.00728 For re-use please see the publisher's terms and conditions.
    ISSN
    0732-183X
    EISSN
    1527-7755
    Sponsors
    The STAMPEDE trial is sponsored by the UK Medical Research Council (MRC_MC_UU_12023/25) and conducted by the MRC Clinical Trials Unit at UCL. The trial is supported by CRUK (CRUK_A12459), the MRC, the NIHR Clinical Research Network, and the Swiss Group for Clinical Cancer Research (SAKK). P.J.H. is supported by NIHR Manchester Biomedical Research Center. The trial also receives industry collaboration and support from Novartis, Sanofi-Aventis, Pfizer, Janssen, Clovis Oncology, and Astellas.
    ae974a485f413a2113503eed53cd6c53
    10.1200/jco.21.00728
    Scopus Count
    Collections
    Faculty of Education, Health and Wellbeing

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.